Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of Kojic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 7/20 | 0.69 |
| ▸ | TYR | P14679 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | IDH1 | O75874 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzil SCHEMBL10422064 | 0.91 | DAO (0.69) | DAOTYRKDM4EIDH1 | |
| Kojic Acid SCHEMBL36895 | 0.83 | TYR (1.00) | DAOTYRKDM4EIDH1 | |
| Kojic Acid SCHEMBL5011817 | 0.83 | TYR (1.00) | DAOTYRKDM4EIDH1 | |
| Kojic Acid SCHEMBL9541984 | 0.82 | TYR (0.81) | DAOTYRKDM4EIDH1 | |
| Kojic Acid SCHEMBL12538255 | 0.81 | TYR (0.96) | DAOTYRKDM4EIDH1 | |
| Kojic Acid SCHEMBL9780977 | 0.81 | TYR (0.96) | DAOTYRKDM4EIDH1 | |
| Kojic Acid SCHEMBL6786872 | 0.81 | TYR (0.96) | DAOTYRKDM4EIDH1 | |
| Kojic Acid SCHEMBL6799291 | 0.80 | DAO (0.85) | DAOTYRKDM4EIDH1 | |
| Kojic Acid SCHEMBL2163795 | 0.79 | TYR (0.92) | DAOTYRKDM4EIDH1 | |
| Kojic Acid SCHEMBL2163798 | 0.79 | TYR (0.92) | DAOTYRKDM4EIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289392-A1 | A MELANOGENESIS INHIBITOR COMPOSITION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-09-17 | — | — | US | claimed |
| EP-3644947-A1 | A MELANOGENESIS INHIBITOR COMPOSITION | Dow Global Technologies LLC (US) | 2020-05-06 | — | — | EP | claimed |
| CN-110769808-A | Melanin production inhibitor composition | 陶氏环球技术有限责任公司 | 2020-02-07 | — | — | CN | claimed |
| WO-2019005437-A1 | A MELANOGENESIS INHIBITOR COMPOSITION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-01-03 | — | — | WO | claimed |
| EP-0308543-B1 | COMPOSITIONS FOR EXTERNAL APPLICATION | Sansho Seiyaku Co., Ltd. (JP) | 1993-09-22 | — | — | EP | claimed |
| US-4990330-A | Skin whitening and sunscreen; Kojic acid of esters, glucosamine and derivatives, cystein | SANSHO SEIYAKU CO., LTD. (JP) | 1991-02-05 | — | — | US | claimed |
| EP-0208799-B1 | WHITENING COSMETIC COMPOSITION | Sansho Seiyaku Co., Ltd. (JP) | 1990-09-26 | — | — | EP | claimed |
| US-4948577-A | KOJIC ACID AND 4-/1,1-DIMETHYLETHYL/-4'-METHOXY DIBENZOYLMETHANE; PREVENT COLORING OF SKIN WHEN EXPOSED TO ULTRAVIOLET LIGHT | SANSHO SEIYAKU CO., LTD. (JP) | 1990-08-14 | — | — | US | claimed |
| EP-0381057-A2 | Chemical composition for external application | Sansho Seiyaku Co., Ltd. (JP) | 1990-08-08 | — | — | EP | claimed |
| US-4919921-A | KOJIC ACID OR AN ESTER OF KOJIC ACID AND VITAMIN C OR A DERIVATIVE OF VITAMIN C | SANSHO SEIYAKU CO., LTD. (JP) | 1990-04-24 | — | — | US | claimed |
| EP-0308543-A1 | Compositions for external application | Sansho Seiyaku Co., Ltd. (JP) | 1989-03-29 | — | — | EP | claimed |
| EP-0308919-A1 | Compositions for topical use having melanin synthesis-inhibiting activity | Sansho Seiyaku Co., Ltd. (JP) | 1989-03-29 | — | — | EP | claimed |
| EP-0308918-A1 | Compositions for topical use having melanin synthesis-inhibiting activity | Sansho Seiyaku Co., Ltd. (JP) | 1989-03-29 | — | — | EP | claimed |
| WO-2024132395-A1 | COLOR STABILIZATION OF FORMULAE WITH AN INDOLE | UNILEVER IP HOLDINGS B.V. (NL) | 2024-06-27 | — | — | WO | disclosed |
| EP-4308071-A1 | USE OF HORDENINE FOR TREATING CELLULAR SENESCENCE | Unilever IP Holdings B.V. (NL) | 2024-01-24 | — | — | EP | disclosed |
| EP-4301329-A1 | USE OF GALACTO-OLIGOSACCHARIDES FOR PROVIDING SKIN CARE BENEFITS | Unilever IP Holdings B.V. (NL) | 2024-01-10 | — | — | EP | disclosed |
| EP-0308543-A1 | Compositions for external application | Sansho Seiyaku Co., Ltd. (JP) | 1989-03-29 | — | — | EP | disclosed |
| EP-0308919-A1 | Compositions for topical use having melanin synthesis-inhibiting activity | Sansho Seiyaku Co., Ltd. (JP) | 1989-03-29 | — | — | EP | disclosed |
| US-4696813-A | PLACENTA EXTRACT AND KOJIC ACID | SANSHO SEIYAKU CO., LTD. (JP) | 1987-09-29 | — | — | US | disclosed |
| EP-0208799-A1 | Whitening cosmetic composition | Sansho Seiyaku Co., Ltd. (JP) | 1987-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289392-A1 | A MELANOGENESIS INHIBITOR COMPOSITION | TYR, MC1R, MITF | DAO 301/4885TYR 1/4885KDM4E 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.